What is the effectiveness of drug-eluting stents in the treatment of ST-elevation myocardial infarction?: Should drug-eluting stents be indicated for patients with acute coronary syndrome? (Pro)

Circulation Journal

Volumn 74, Issue 10, 2010, Pages 2225-2231

  Nakagawa, Yoshihisa ^a  

^a TENRI HOSPITAL   (Japan)

Author keywords

Acute coronary syndrome; Drug eluting stent; Percutaneous coronary intervention; Reperfusion; Restenosis

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PACLITAXEL; RAPAMYCIN; TIROFIBAN;

ACUTE CORONARY SYNDROME; ARTICLE; BARE METAL STENT; CLINICAL TRIAL; DISEASE REGISTRY; DRUG ELUTING STENT; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; JAPAN; MORTALITY; OUTCOME ASSESSMENT; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; RECURRENT DISEASE; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT INDICATION; TREND STUDY;

ACUTE CORONARY SYNDROME; DATA COLLECTION; DRUG-ELUTING STENTS; HUMANS; META-ANALYSIS AS TOPIC; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REGISTRIES; STENTS; TREATMENT OUTCOME;

EID: 77958056801     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0729     Document Type: Article

References (52)

1. Hartzler GO, Rutherford BD, McConahay DR, Johnson WL Jr, McCallister BD, Gura GM Jr, et al. Percutaneous transluminal coronary angioplasty with and without thrombolytic therapy for treatment of acute myocardial infarction. Am Heart J 1983; 106: 965-973.
2. Nakagawa Y, Iwasaki Y, Kimura T, Tamura T, Yokoi H, Yokoi H, et al. Serial angiographic follow-up after successful direct angioplasty for acute myocardial infarction. Am J Cardiol 1996; 78: 980-984.
3. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 1999; 341: 1949-1956.
4. Bauer T, Hoffmann R, Junger C, Koeth O, Zahn R, Gitt A, et al. Efficacy of a 24-h primary percutaneous coronary intervention service on outcome in patients with ST elevation myocardial infarction in clinical practice. Clin Res Cardiol 2009; 98: 171-178.
5. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Biondi-Zoccai G, Kastrati A, et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: A meta-regression analysis of randomized trials. Int J Cardiol 2008; 126: 37-44.
6. Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark LT. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: A meta-analysis of randomized clinical trials. Am J Cardiol 2001; 88: 297-301.
7. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
8. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
9. Hoffmann R, Klinker H, Adamu U, Kelm M, Blindt R. The risk of definitive stent thrombosis is increased after "off-label" stent implantation irrespective of drug-eluting stent or bare-metal stent use. Clin Res Cardiol 2009; 98: 549-554.
10. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006; 98: 352-356.
11. Guidelines for the management of patients with ST-elevation myocardial infarction (JCS 2008). Circ J 2008; 72(Suppl): 1347-1411.
12. Lemos PA, Saia F, Hofma SH, Daemen J, Ong AT, Arampatzis CA, et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004; 43: 704-708.
13. Hannan EL, Racz M, Walford G, Holmes DR, Jones RH, Sharma S, et al. Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol Interv 2008; 1: 129-135.
14. Campo G, Saia F, Percoco G, Manari A, Santarelli A, Vignali L, et al. Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: Data from the REAL Registry. Int J Cardiol 2010; 140: 154-160.
15. Mauri L, Silbaugh TS, Garg P, Wolf RE, Zelevinsky K, Lovett A, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 2008; 359: 1330-1342.
16. Brodie BR, Stuckey T, Downey W, Humphrey A, Nussbaum M, Laurent S, et al. Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: Results from the Strategic Transcatheter Evaluation of New Therapies (STENT) group. Catheter Cardiovasc Interv 2008; 72: 893-900.
17. Pierre-Louis B, Aronow WS, Palaniswamy C, Singh T, Ahn C, Asija A, et al. Major adverse cardiac events at follow-up after bare-metal stenting versus drug-eluting stenting in ST-elevated myocardial infarction. Am J Cardiol 2009; 103: 1672-1674.
18. Steg G, Fox KA, Eagle KA, Furman M, Werf F, Montalescot G, et al. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J 2009; 30: 321-329.
19. Saia F, Lemos PA, Lee CH, Arampatzis CA, Hoye A, Degertekin M, et al. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction: A clinical and angiographic study. Circulation 2003; 108: 1927-1929.
20. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 55: 1093-1104.
21. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: A randomized trial. JAMA 2005; 293: 2109-2117.
22. Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: The MULTISTRATEGY randomized trial. JAMA 2008; 299: 1788-1799.
23. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 55: 1105-1113.
24. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009; 360: 1946-1959.
25. Chechi T, Vittori G, Biondi Zoccai GG, Vecchio S, Falchetti E, Spaziani G, et al. Single-center randomized evaluation of paclitaxel- eluting versus conventional stent in acute myocardial infarction (SELECTION). J Interv Cardiol 2007; 20: 282-291.
26. Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, et al. Randomized trial of sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction (SESAMI). J Am Coll Cardiol 2007; 49: 1924-1930.
27. Diaz de la Llera LS, Ballesteros S, Nevado J, Fernandez M, Villa M, Sanchez A, et al. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J 2007; 154: 164-166.
28. van der Hoeven BL, Liem SS, Jukema JW, Suraphakdee N, Putter H, Dijkstra J, et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2008; 51: 618-626.
29. Kelbaek H, Thuesen L, Helqvist S, Clemmensen P, Klovgaard L, Kaltoft A, et al. Drug-eluting versus bare-metal stents in patients with ST-segment-elevation myocardial infarction: Eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 2008; 118: 1155-1162.
30. Okada H, Mutou M, Hasuda T, Ishikawa T, Tajima O, Imai K. Initial and mid-term results of sirolimus-eluting stent implantation in acute coronary syndrome: A comparison with bare metal stenting. Jpn J Interv Cardiol 2007; 22: 219-223 (in Japanese).
31. Endo S, Kinugasa Y, Osaki S, Ohtahara A, Kasahara T. Early and mid-term outcomes after Sirolimus-eluting stent implanatation in patients with acute myocardial infarction. Jpn J Cardiovasc Catheter Ther 2007; 7: 345-352 (in Japanese).
32. Dai K, Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, et al. One year outcomes of Cypher stent implantation for patients with acute myocardial infarction. Jpn J Interv Cardiol 2008; 23: 350-355.
33. Nomoto K, Watanabe I, Oba T, Nagao K, Kushiro T, Hirayama A. Safety and efficacy of Sirolimus-eluting stent in patients with acute coronary syndrome undergoing emergency procedure. Circ J 2008; 72: 1054-1058.
34. Sugiyama H, Shimizu S, Watanabe Y, Deyama J, Hashiguchi N, Onodera S, et al. Short and middle term outcomes of coronary stenting with Sirolimus-eluting stents and bare metal stents in patients with acute myocardial infarction. Jpn J Interv Cardiol 2008; 23: 248-253 (in Japanese).
35. Ogita M, Nakamura T, Fujiwara N, Sakakura K, Funayama H, Sugawara Y, et al. Long-term clinical follow-up after Sirolimuseluting stent versus bare metal stent implantation in patients with acute coronary syndrome. J Interv Cardiol 2009; 22: 216-221.
36. Horibe H, Kawamura S, Kodama N, Nakagawa K, Murata Y, Kawai H, et al. Clinical outcomes of primary stenting for acute coronary syndrome based on selective use of sirolimus-eluting Stents. Jpn J Interv Cardiol 2009; 24: 13-20 (in Japanese).
37. Yoshikawa D, Isobe S, Umeda H, Kawai T, Shimizu T, Yamashita K, et al. Three-year prognosis of Japanese patients with ST-elevation myocardial infarction treated with sirolimus-eluting stents. Coron Artery Dis 2009; 20: 422-427.
38. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009; 119: 987-995.
39. Kawaguchi R, Kimura T, Morimoto T, Oshima S, Hoshizaki H, Kawai K, et al. Safety and efficacy of sirolimus-eluting stent implantation in patients with acute coronary syndrome in the real world. Am J Cardiol 2010 (in press).
40. De Luca G, Stone GW, Suryapranata H, Laarman GJ, Menichelli M, Kaiser C, et al. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. Int J Cardiol 2009; 133: 213-222.
41. Pasceri V, Patti G, Speciale G, Pristipino C, Richichi G, Di Sciascio G. Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J 2007; 153: 749-754.
42. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al. Meta-analysis of randomized trials on drugeluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007; 28: 2706-2713.
43. Dibra A, Tiroch K, Schulz S, Kelbæk H, Spaulding C, Laarman GJ, et al. Drug-eluting stents in acute myocardial infarction: Updated meta-analysis of randomized trials. Clin Res Cardiol 2010; 99: 345-357.
44. Nakagawa Y, Kimura T, Morimoto T, Nomura M, Saku K, Haruta S, et al. Incidence and risk factors of late target-lesion revascularization after Sirolimus-eluting stent implantation. Am J Cardiol 2010; 106: 329-336.
45. Nakagawa Y. DES vs. BMS in patients with ST-elevation myocardial infarction, from j-Cypher registry (Should drug eluting stents be indicated for the patients with acute coronary syndrome?) (abstract). Circ J 2009; 78(Suppl): 78.
46. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: An autopsy study. Circulation 2008; 118: 1138-1145.
47. Nakagawa Y, Nobuyoshi M, Yamaguchi T, Meguro T, Yokoi H, Kimura T, et al. Efficacy of abciximab for patients undergoing balloon angioplasty: Data from Japanese Evaluation of c7E3 Fab for Elective and Primary PCI Organization in Randomized Trial (JEPPORT). Circ J 2009; 73: 145-151.
48. Hoshino K, Horiuchi H, Tada T, Tazaki J, Nishi E, Kawato M, et al. Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention. Circ J 2009; 73: 336-342.
49. Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M, et al. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circ J 2009; 73: 1498-1503.
50. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, et, al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: A subanalysis of a randomised trial. Lancet 2008; 371: 1353-1363.
51. Inoue K. Drug-eluting stents are not indicated for patients with acute coronary syndrome: Should drug-eluting stents be indicated for patients with acute coronary syndrome (con)? Circ J 2010; 74: 2232-2238.
52. Yamaji K, Kimura T, Morimoto T, Nakagawa Y, Inoue K, Soga Y, et al. Very long-term (15-20 Years) follow-up after coronary baremetal stent implantation. Circ Cardiovasc Interv 2010 (in press).